PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Pfizer Worldwide Research, Development & Medical, Cambridge, MA 02139, USA.\', \'Pfizer Worldwide Research, Development & Medical, Pearl River, NY 10965, USA.\', \'Pfizer Worldwide Research, Development & Medical; Groton, CT 06340, USA.\', \'Pfizer Worldwide Research, Development & Medical, La Jolla, CA 92121, USA.\', \'Institute for Antiviral Research, Department of Animal, Dairy, and Veterinary Sciences, Utah State University; Logan, UT 84322, USA.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1126/science.abl4784
?:doi
?:hasPublicationType
?:journal
  • Science (New York, N.Y.)
is ?:pmid of
?:pmid
?:pmid
  • 34726479
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
?:title
  • An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all